证券代码：300009 证券简称：安科生物 公告编号：2024-024 安徽安科生物工程（集团）股份有限公司 关于增补第八届董事会非独立董事的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 安徽安科生物工程（集团）股份有限公司（以下简称"公司"）于 2024 年 4 月 18 日召开的公司 2023 年度股东大会审议通过了《关于增补第八届董事会非 独立董事的议案》， 同意增补杜贤宇先生（简历详见附件）为公司第八届董事会 非独立董事，任期自本次大会审议通过之日起至第八届董事会任期届满之日止。 具体情况如下： 为符合《公司章程》规定的董事会成员人数，完善公司治理，经公司 2024 年 3 月 25 日独立董事专门会议对杜贤宇先生任职资格审查通过后，2024 年 3 月 26 日公司第八届董事会第十次会议审议通过了《关于增补第八届董事会非独立 董事的议案》，并提交公司 2023 年度股东大会审议。 安徽安科生物工程（集团）股份有限公司 董事会 2024 年 4 月 18 日 附件： 安徽安科生物工程（集团）股份有限公司 杜贤宇先生简历 杜贤宇先生，中国国籍，未拥有 ...

法律意见书 安徽天禾律师事务所 关于安徽安科生物工程(集团)股份有限公司 2023年年度股东大会 之法律意见书 天律意2024第00816号 致：安徽安科生物工程(集团)股份有限公司 根据《中华人民共和国公司法》(下称"《公司法》")、《中华人民共和国 证券法》(下称"《证券法》")、中国证券监督管理委员会《上市公司股东大会 规则》(下称"《股东大会规则》")以及《安徽安科生物工程(集团)股份有限公 司章程》(下称"《公司章程》")等有关规定，安徽天禾律师事务所接受安徽安 科生物工程(集团)股份有限公司(下称"安科生物"或"公司")委托，指派王炜 律师、陈崇红律师(下称"本所律师")出席公司2023年年度股东大会(下称"本 次股东大会")，对本次股东大会相关事项进行见证，并出具法律意见。本法律 意见书是本所律师根据对有关本次股东大会事实的了解及对现行法律、法规和规 范性文件的理解而做出的。本所律师同意将本法律意见书作为本次股东大会的必 备文件予以公告并依法对所出具的法律意见书承担责任。 本所律师根据有关法律、法规的要求，按照律师行业公认的业务标准、道德 规范和勤勉尽责的精神，对本次股东大会的召集和召开程序、出 ...

证券代码：300009 证券简称：安科生物 公告编号：2024-023 安徽安科生物工程（集团）股份有限公司 2023 年度股东大会决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 特别提示： 1、本次股东大会无否决议案的情形； 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间 现场会议召开时间：2024 年 4 月 18 日（星期四）上午 09:30 网络投票时间： （1）通过深圳证券交易所交易系统进行网络投票的时间为：2024 年 4 月 18 日 09:15 至 09:25，09:30 至 11:30，13:00 至 15:00； （2）通过深圳证券交易所互联网投票系统投票的具体时间为：2024 年 4 月 18 日 09:15 至 4 月 18 日 15:00 期间的任意时间。 2、现场会议地点：合肥市高新区海关路 K-1 安徽安科生物工程（集团）股 份有限公司（以下简称"公司"）A 座 1201 会议室 3、召开方式：本次股东大会采取现场表决与网络投票相结合的方式召开。 4、会议召 ...

⚫ 持续加大研发投入，夯实研发创新能力。2023 年，公司研发投入 2.55 亿元（+53.41%），公司持续加大研发投入工作和新品开发力度，为未 来高质量发展提供有力保障。在研产品进展方面，公司自主研发的 "AK2017 注射液"（重组人生长激素-Fc 融合蛋白注射液快速推进）， 已完成 I 期临床试验并进入 II 期临床试验阶段，有望进一步丰富在儿 童生长发育领域的产品线。人干扰素 α2b 喷雾剂用于治疗由病毒感染 引起的儿童疱疹性咽峡炎的临床试验正在开展Ⅱ期临床研究。 ⚫ 盈利预测与投资建议。我们预计公司 2024-2026 年 EPS 分别为 0.63 SAC 执证号：S0260516090004 SFC CE No. BOR756 安科生物（300009.SZ）:生 2023-08-25 长激素持续放量，研发管线 稳步推进 [Table_ResearchTeam] 广发医药行业研究小组 | --- | --- | |----------------------------|------------| | | | | [ 公司评级 Table_Invest] | 买入 | | 当前价格 | 9.92 ...

二、补充披露董事会对会计师事务所 2023 年度履职情况的评估报告及审计 委员会对会计师事务所履行监督职责情况的报告 公司于 2024 年 3 月 26 日召开第八届董事会第十次会议审议通过《关于续聘 公司 2024 年度审计机构的议案》，并将本议案提交至公司 2023 年度股东大会待 审议。 证券代码：300009 证券简称：安科生物 公告编号：2024-022 安徽安科生物工程（集团）股份有限公司 关于 2023 年度股东大会部分议案内容补充披露的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 安徽安科生物工程（集团）股份有限公司（下称"公司"）定于 2024 年 4 月 18 日（星期四）上午 9:30 在合肥市高新区海关路 K-1 公司 A 座 1201 会议室 召开公司 2023 年度股东大会。为便于投资者充分了解本次股东大会审议事项的 内容，现将本次股东大会部分议案内容进行补充披露。 一、补充披露《公司 2023 年度报告及其摘要》、《公司 2023 年度财务决算 报告》的审计委员会意见 公司第八届董事会审计委员 2024 年第一次会议于 202 ...

Investment Rating - The investment rating for the company is "Buy (Maintain)" [7] Core Views - The company has shown strong growth in its main product, growth hormone, with a sales revenue increase of 36.24% in 2023, contributing significantly to the overall performance [7][8] - The approval of Trastuzumab injection is expected to provide additional revenue for the company, with plans for full-scale production in 2024 [7][8] - The company is actively increasing its R&D efforts, with a 53.41% year-on-year increase in R&D expenses in 2023, focusing on both biopharmaceuticals and targeted cancer drugs [7][8] Financial Forecast - Main revenue (in million yuan) is projected to grow from 2,866 in 2023 to 3,583 in 2024, 4,378 in 2025, and 5,296 in 2026, with growth rates of 22.9%, 25.0%, 22.2%, and 21.0% respectively [3][11] - Net profit attributable to shareholders (in million yuan) is expected to rise from 847 in 2023 to 1,080 in 2024, 1,360 in 2025, and 1,685 in 2026, with growth rates of 20.5%, 27.5%, 25.9%, and 23.9% respectively [3][11] - The diluted earnings per share (in yuan) are forecasted to increase from 0.51 in 2023 to 0.64 in 2024, 0.81 in 2025, and 1.01 in 2026 [3][11] - The return on equity (ROE) is projected to improve from 21.5% in 2023 to 24.0% in 2024, 26.1% in 2025, and 27.6% in 2026 [3][11]

安徽安科生物工程（集团）股份有限公司（以下简称"公司"）已于2024年3 月28日披露了公司2023年年度报告及其摘要。 证券代码：300009 证券简称：安科生物 公告编号：2024-020 安徽安科生物工程（集团）股份有限公司 关于召开 2023 年度业绩网上说明会的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 特此公告。 为便于广大投资者进一步了解公司2023年度经营情况，公司将于2024年4月 11日（星期四）下午15:00至17:00在"约调研"小程序举行2023年度业绩网上说 明会。本次业绩说明会将采用网络远程的方式举行，投资者可登陆"约调研"小 程序参与互动交流。为广泛听取投资者的意见和建议，现就公司2023年度业绩说 明会提前向投资者征集问题，提问通道自本公告披露之日起开放。 安徽安科生物工程（集团）股份有限公司 董事会 参与方式一：在微信小程序中搜索"约调研"； 出席本次业绩说明会的人员有：公司董事长、总裁宋礼华先生，独立董事刘 光福先生，执行总裁姚建平先生，董事、董事会秘书李坤先生，副总裁窦颖辉先 生，副总裁陆春燕女士，副总裁鲍学科先生 ...

Financial Performance - The company's operating revenue for 2023 reached ¥2,865,752,059.95, representing a 22.94% increase compared to ¥2,331,062,727.29 in 2022[14] - Net profit attributable to shareholders was ¥847,229,426.30, up 20.47% from ¥703,323,479.92 in the previous year[14] - The net profit after deducting non-recurring gains and losses was ¥809,324,373.22, reflecting a 26.07% increase from ¥642,026,644.47 in 2022[14] - The net cash flow from operating activities was ¥952,970,899.58, a 36.34% increase compared to ¥698,977,608.26 in 2022[14] - The total assets at the end of 2023 amounted to ¥4,950,760,486.04, which is a 16.30% increase from ¥4,255,325,817.63 at the end of 2022[14] - The company's net assets attributable to shareholders increased by 16.48% to ¥3,737,399,547.01 from ¥3,208,622,822.65 in 2022[14] - The company reported total operating income of 2.1 billion yuan for the year, with a quarterly breakdown showing a peak of 844.37 million yuan in Q4[43] - The net profit attributable to shareholders for Q4 was 192.81 million yuan, with a total of 210.74 million yuan in Q2 and 258.06 million yuan in Q3[43] - The company has achieved a compound annual growth rate (CAGR) of over 21% in operating revenue and over 23% in net profit attributable to shareholders since its IPO in 2009[61] Business Strategy and Development - The company is focusing on innovative drug development, including ADC drugs and mRNA therapies, to enhance its product pipeline[21] - The company aims to continue its strategic investments in cutting-edge biopharmaceutical technologies and expand its market reach through innovative product offerings[21] - The company is focusing on innovation in new product development and enhancing its core competitiveness to drive high-quality growth[51] - The company is actively exploring project and technology cooperation for external growth while integrating subsidiary resources to support overall performance[54] - The company is responding to national policies by implementing a "going out" strategy to enhance its international presence in the biopharmaceutical sector[49] - The company plans to enhance the utilization rate and economic benefits of the HER2 monoclonal antibody project through market promotion and sales efforts[58] - The company is committed to improving its governance structure and internal management systems to enhance decision-making and protect the rights of minority investors[78] - The company aims to create a diversified collaborative development model centered on its main business while strengthening internal management systems[57] - The company plans to adjust its business structure by deregistering wholly-owned subsidiaries, including Hefei Yuga Information Technology Co., Ltd. and Nanjing Dikon Jinnuo Medical Testing Co., Ltd.[89] Research and Development - The company is advancing the clinical trials for its recombinant human growth hormone-FC fusion protein injection and other new indications, as well as new specifications for its products[74] - The company is accelerating the clinical progress of innovative drugs such as HuA21 injection and expanding its product pipeline in the oncology treatment field[75] - The company completed the third phase of clinical trials for its anti-VEGF monoclonal antibody, aiming for market launch, which is expected to enhance its oncology product line[109] - The total R&D investment amounted to ¥257,743,838.56 in 2023, representing 8.99% of operating revenue, compared to 8.43% in 2022[109] - The number of R&D personnel increased to 479 in 2023, a growth of 1.91% from 470 in 2022, with a higher proportion holding master's degrees[109] - The company adheres to a research and development strategy of "producing one generation, developing one generation, pre-researching one generation, and reserving one generation" to enhance its independent R&D capabilities while collaborating with top domestic research institutions and innovative pharmaceutical companies[200] - The R&D model combines independent innovation with industry-academia-research cooperation and new product introduction[200] Market and Sales Performance - Revenue from biological products was ¥2,099,775,209.52, accounting for 73.27% of total revenue, with a year-on-year growth of 34.93%[84] - The gross profit margin for biological products was 85.70%, a decrease of 1.31% from the previous year[84] - Domestic sales in East China (excluding Anhui) amounted to ¥1,062,123,578.67, up 28.75% from ¥824,924,499.70 in 2022[84] - The sales revenue from traditional Chinese medicine decreased by 11.42% to ¥358,249,174.00, with a gross profit margin of 80.61%[84] - The company experienced a 27.28% decline in foreign sales, totaling ¥2,983,075.21[84] - The company established three new subsidiaries in 2023, enhancing its operational capacity and market reach[104] - The company aims to become a leading provider of health products and services, with a vision of achieving "100 billion Anke, 100 years Anke" in its development strategy[95] - The company will continue to optimize and upgrade existing products while expanding its product line in the field of tumor treatment[95] Governance and Investor Relations - The company emphasizes the importance of independent directors in governance, ensuring that their interests, especially those of minority shareholders, are protected[94] - The company has established a governance structure that complies with relevant laws and regulations, ensuring effective communication with investors and enhancing information disclosure quality[63] - The company has implemented strict confidentiality measures regarding insider information, ensuring compliance with relevant regulations[148] - The company is committed to enhancing investor relations management to improve information transparency and protect the rights of all shareholders, especially minority shareholders[147] - The company emphasizes the importance of maintaining effective communication with investors through various channels, including a dedicated investor hotline and official social media accounts[147] - The company has conducted multiple investor communications, including on-site visits and online exchanges, to discuss operational performance and R&D progress[59] Financial Management - The company raised a total of RMB 682,039,998.08 for four fundraising projects, with a net amount of RMB 663,487,998.08 after deducting issuance costs[58] - The company has implemented a cash dividend policy, distributing a total of RMB 1.827 billion in cash dividends over 14 years, which is 1.85 times the actual funds raised during its IPO and refinancing[62] - The company reported a significant increase in financial expenses, which rose by 59.17% to -¥3,809,223.53 in 2023, attributed to increased interest income from deposits[108] - The net cash flow from financing activities was -400,994,096.55, a decrease of 161.83% compared to the previous year[131] - Cash and cash equivalents decreased by 65,402,131.38, representing a decline of 3,359.85% year-over-year[131] Risks and Challenges - The company faces risks related to new drug development not meeting expectations, which could impact profitability and growth potential[79] - The company is also addressing risks from industry policy changes and centralized procurement that may lead to price reductions for its products[80]

Investment Rating - The report maintains a "Buy" rating for the company [9][28]. Core Views - The company achieved a revenue of 2.866 billion RMB in 2023, representing a year-on-year growth of 23%. The net profit attributable to the parent company was 847 million RMB, up 20% year-on-year [29]. - The growth in revenue is primarily driven by the rapid increase in sales of growth hormone products, which saw a year-on-year increase of 36.24% [29]. - The company is actively investing in research and development, with R&D expenses increasing by 53.41% to 255 million RMB in 2023, supporting the development of new products and enhancing existing ones [29]. Summary by Sections Financial Performance - The company is projected to achieve net profits of 1.073 billion RMB (+27%), 1.351 billion RMB (+26%), and 1.699 billion RMB (+26%) for the years 2024 to 2026, respectively [9]. - The earnings per share (EPS) for 2024, 2025, and 2026 are expected to be 0.64 RMB, 0.81 RMB, and 1.01 RMB, corresponding to price-to-earnings (P/E) ratios of 15, 12, and 9 times [9]. Revenue and Profit Growth - The company’s revenue is expected to grow from 2.331 billion RMB in 2022 to 3.610 billion RMB in 2024, reflecting a growth rate of 25.99% [13]. - The net profit attributable to the parent company is projected to increase from 703 million RMB in 2022 to 1.073 billion RMB in 2024, with a growth rate of 26.66% [13]. R&D and Product Development - The company is focusing on the development of targeted anti-tumor drugs and has made significant progress in clinical trials for several products, including "AK2017 injection" and "AK1012 inhalation solution" [29]. - The product pipeline is expected to continue expanding, providing a solid foundation for long-term growth [29].

证券代码：300009 证券简称：安科生物 公告编号：2024-012 安徽安科生物工程（集团）股份有限公司 关于使用闲置自有资金进行现金管理的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 安徽安科生物工程（集团）股份有限公司（以下简称"公司"）于 2024 年 3 月 26 日召开的第八届董事会第十次会议审议通过了《关于使用闲置自有资金进 行现金管理的议案》，同意公司在确保资金安全、操作合法合规、保证正常生产 经营不受影响的前提下，使用不超过 18 亿元人民币的闲置自有资金通过金融机 构进行现金管理，在确保安全性、流动性的基础上实现资金的保值增值。在上述 额度内，资金可以滚动使用，使用期限为自本次股东大会审议通过之日起 14 个 月内有效，单个理财产品的投资期限不超过 12 个月，并授权公司董事长在上述 额度内行使决策权。 为提高资金使用效率，合理利用闲置自有资金，在不影响公司正常经营的情 况下，利用暂时闲置的自有资金进行现金管理，增加资金效益，更好地实现公司 资金的保值增值，保障公司股东的利益。 一、现金管理情况概述 1、现金管理的目的 2、资金来源及 ...